Do you think it is always necessary to validate surrogate endpoints in specific studies before using them in the trials?

Do you know studies which aimed at evaluating surrogate endpoints in digestive oncology?

If several clinical trials demonstrate efficacy of a treatment on another endpoint than overall survival,

a- does it encourage you to use this treatment in your current practice?

b- do you verify if this endpoint has been validated as surrogate endpoint?